IGI Logo

Growth to accelerate

RAINBOW delivered modest EBITDA growth of 11% CAGR over FY23-26, reflecting the absorption of ~780 beds added during its aggressive expansion cycle, which has now largely concluded. The company continues to benefit from industry-leading margins, strong FCF generation, a net cash balance sheet, and healthy return ratios, aided by its asset-light hub-and-spoke model, unique position as India’s only integrated multispecialty pediatric healthcare platform, and differentiated full-time doctor engagement model. With newly commissioned capacities entering the ramp-up phase and occupancy levels expected to improve, we forecast Pre IND-AS EBITDA growth of 20% CAGR over FY26–FY28E. Strategic expansion across its core markets in South India along with entry into newer markets augurs well for its sustainable growth. At CMP, the stock trades at 20x EV/EBITDA on FY28E. We recommend ‘BUY’ rating with TP of INR1,700/share, based on 26x FY28E Pre-IND-AS EV/EBITDA.

Entering consolidation phase:

RAINBOW has largely concluded its FY23–FY26 expansion cycle, adding ~780 beds (~47% capacity growth), and is now entering a consolidation phase focused on occupancy ramp-up and margin expansion over FY26- 28E. The recently acquired Warangal and Guwahati hospitals have integrated seamlessly into the network and are already contributing to 7–8% of revenue, demonstrating the company’s ability to execute and scale inorganic growth initiatives effectively. In addition, the newly commissioned Bengaluru facility (HRBR, Electronic City) is also witnessing strong traction, supported by the onboarding of renowned consultants and healthy patient volumes.

Occupancy recovery to be driven by new initiatives and clinical mix:

The slowdown in FY26 was largely driven by seasonal headwinds and start-up losses of new bed commissioning. Recently, RAINBOW has strengthened its growth engine through leadership appointments, including a new CEO, Chief Growth Officer and hiring new clinical talents with more focus on tertiary and quaternary cases. CRM-led physician engagement and digital patient acquisition are also aiding better conversions. This will aid better clinical mix and help them to reduce dependence on seasonality. Overall, we expect mature unit’s occupancy to normalize toward 56-58% in FY28 from current level of 51%. Further upside is expected from the gradual ramp-up of the international patient business.

Next leg of growth through internally funded bed expansion:

RAINBOW has already secured the next leg of growth through a calibrated 900+ bed expansion pipeline across Gurugram (flagship hub), Coimbatore, Pune, Bangalore and Indore. With the FY23–26 capex cycle largely behind, all new facilities are targeted to be operational from H2FY28 onwards. Importantly, the entire INR10–11bn capex program will be funded through internal accruals with no incremental debt.

Strong FCF generation continue:

RAINBOW exhibits sector-leading capital efficiency with a debt-free balance sheet and a net cash position of INR6bn, despite its largest-ever expansion cycle. The company expects to fund its INR10bn+ capex pipeline entirely through internal accruals, reflecting strong cash flow visibility. Supported by its asset-light hub-and-spoke model and full-time doctor structure, RAINBOW is well placed to sustain superior return ratios. As occupancy normalizes across mature and newly commissioned facilities, OCF generation should accelerate over FY26–28E, enabling self-funded growth, improving returns, and providing medium-term capital allocation flexibility

Please refer disclaimer at https://www.plindia.com/disclaimer/

SEBI Registration No. INH000000271